A widely recommended approach for the control of hyperglycemia is to administer a parenteral insulin preparation that provides a constant source of circulating insulin for 12–24 h to augment or replace deficient endogenous insulin secretion, although insulin resistance is eventually developed in these insulin-treated patients [25]. Here, INS is linked to Insulin resistance.